内部人士在盈利失利、诉讼和股价下跌期间，卖出了170万美元的Ultragenyx股票。 Insiders sold $1.7M in Ultragenyx stock amid earnings miss, lawsuit, and declining shares.

2026年3月2日,Ultragenyx制药公司的内部人士,包括首席执行官Emil Kakkis,执行副总裁Karah Herdman Parschauer和首席会计官Theodore Alan Huizenga,以每股22.80美元的价格出售了74,160股RARE股票,总额为170万美元. On March 2, 2026, Ultragenyx Pharmaceutical insiders, including CEO Emil Kakkis, executive vice president Karah Herdman Parschauer, and chief accounting officer Theodore Alan Huizenga, sold a combined 74,160 shares of RARE stock at $22.80 per share, totaling $1.7 million. 此次出售使持股减少3%，降至10%，公司股价于3月3日收盘价为22.07美元，下跌0.95美元。 The sales reduced their stakes by 3% to 10%, with the company’s stock closing at $22.07 on March 3, down $0.95. Ultragenyx报告说,2025年的Q4收入为每股1.29美元的亏损,缺少估计数,尽管收入增加25.5%,达到2.0728亿美元。 Ultragenyx reported Q4 2025 earnings of a $1.29 loss per share, missing estimates, though revenue rose 25.5% to $207.28 million. 从2023年8月至2025年12月,该公司面临证券欺诈集体诉讼诉讼,要求披露2023年8月至2025年12月的Setrusumab,分析家预测本年度每股损失5.18美元。 The company faces a securities-fraud class action lawsuit over setrusumab disclosures from August 2023 to December 2025, and analysts project a $5.18 loss per share for the current year. 尽管已达成共识的“机动购买”评级和平均价格目标为68.29美元,但最近内幕出售和法律风险加剧了市场关切。 Despite a consensus “Moderate Buy” rating and an average price target of $68.29, recent insider selling and legal risks have heightened market concerns.